3. Abraham AL et al (2012) Genetic modifiers of chromatin acetylation antagonize the
reprogramming of epi-polymorphisms. PLoS Genet 8(9):e1002958
4. Bierne H, Hamon M, Cossart P (2012) Epigenetics and bacterial infections. Cold Spring
Harb Perspect Med 2(12):a010272
5. Brookes E, Shi Y (2014) Diverse epigenetic mechanisms of human disease. Annu Rev Genet
48:237–268
6. Epigenetics Drugs and Diagnostic Technologies Market - Global Industry Analysis, Size,
Share, Growth, Trends and Forecast, 2012–2018
7. Raynal NJ et al (2017) Repositioning FDA-approved drugs in combination with epigenetic
drugs to reprogram colon cancer epigenome. Mol Cancer Ther 16(2):397–407
8. Mendez-Lucio O et al (2014) Toward drug repurposing in epigenetics: olsalazine as a
hypomethylating compound active in a cellular context. ChemMedChem 9(3):560–565
9. Raynal NJ et al. (2014) Discovery of new epigenetic drugs among FDA-approved drug
libraries. Cancer Res. 74:19
10. Portela A, Esteller M (2010) Epigenetic modifications and human disease. Nat Biotechnol
28(10):1057–1068
11. Bhattacharjee D, Shenoy S, Bairy KL (2016) DNA methylation and chromatin remodeling:
the blueprint of cancer epigenetics. Scientifica (Cairo) 2016:6072357
12. Virani S et al (2012) Cancer epigenetics: a brief review. ILAR J 53(3–4):359–369
13. Sen P et al (2016) Epigenetic mechanisms of longevity and aging. Cell 166(4):822–839
14. Benayoun BA, Pollina EA, Brunet A (2015) Epigenetic regulation of ageing: linking
environmental inputs to genomic stability. Nat Rev Mol Cell Biol 16(10):593–610
15. Ling C, Groop L (2009) Epigenetics: a molecular link between environmental factors and
type 2 diabetes. Diabetes 58(12):2718–2725
16. Landgrave-Gomez J, Mercado-Gomez O, Guevara-Guzman R (2015) Epigenetic mechanisms in neurological and neurodegenerative diseases. Front Cell Neurosci 9:58
17. Coppede F (2014) The potential of epigenetic therapies in neurodegenerative diseases. Front
Genet 5:220
18. Lee J et al (2013) Epigenetic mechanisms of neurodegeneration in Huntington’s disease.
Neurotherapeutics 10(4):664–676
19. Peedicayil J (2016) Epigenetic drugs for multiple sclerosis. Curr Neuropharmacol 14(1):3–9
20. Relle M, Foehr B, Schwarting A (2015) Epigenetic aspects of systemic lupus erythematosus.
Rheumatol Ther 2(1):33–46
21. Wu H et al (2015) The real culprit in systemic lupus erythematosus: abnormal epigenetic
regulation. Int J Mol Sci 16(5):11013–11033
22. Hedrich CM (2017) Epigenetics in SLE. Curr Rheumatol Rep 19(9):58
23. Klein K, Ospelt C, Gay S (2012) Epigenetic contributions in the development of rheumatoid
arthritis. Arthritis Res Ther 14(6):227
24. Bernstein BE, Meissner A, Lander ES (2007) The mammalian epigenome. Cell 128(4):
669–681
25. Wang Z et al (2008) Combinatorial patterns of histone acetylations and methylations in the
human genome. Nat Genet 40(7):897–903
26. Kaminskas E et al (2005) FDA drug approval summary: azacitidine (5-azacytidine, Vidaza)
for injectable suspension. Oncologist 10(3):176–182
27. Von Hoff DD, Slavik M, Muggia FM (1976) 5-Azacytidine. A new anticancer drug with
effectiveness in acute myelogenous leukemia. Ann Intern Med 85(2):237–245
28. Joeckel TE, Lubbert M (2012) Clinical results with the DNA hypomethylating agent
5-aza-2’-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Semin Hematol 49(4):330–341
29. Mann BS et al (2007) FDA approval summary: vorinostat for treatment of advanced primary
cutaneous T-cell lymphoma. Oncologist 12(10):1247–1252
30. Galanis E et al (2009) Phase II trial of vorinostat in recurrent glioblastoma multiforme: a
north central cancer treatment group study. J Clin Oncol 27(12):2052–2058
Integrated Chemoinformatics Approaches …
265
reprogramming of epi-polymorphisms. PLoS Genet 8(9):e1002958
4. Bierne H, Hamon M, Cossart P (2012) Epigenetics and bacterial infections. Cold Spring
Harb Perspect Med 2(12):a010272
5. Brookes E, Shi Y (2014) Diverse epigenetic mechanisms of human disease. Annu Rev Genet
48:237–268
6. Epigenetics Drugs and Diagnostic Technologies Market - Global Industry Analysis, Size,
Share, Growth, Trends and Forecast, 2012–2018
7. Raynal NJ et al (2017) Repositioning FDA-approved drugs in combination with epigenetic
drugs to reprogram colon cancer epigenome. Mol Cancer Ther 16(2):397–407
8. Mendez-Lucio O et al (2014) Toward drug repurposing in epigenetics: olsalazine as a
hypomethylating compound active in a cellular context. ChemMedChem 9(3):560–565
9. Raynal NJ et al. (2014) Discovery of new epigenetic drugs among FDA-approved drug
libraries. Cancer Res. 74:19
10. Portela A, Esteller M (2010) Epigenetic modifications and human disease. Nat Biotechnol
28(10):1057–1068
11. Bhattacharjee D, Shenoy S, Bairy KL (2016) DNA methylation and chromatin remodeling:
the blueprint of cancer epigenetics. Scientifica (Cairo) 2016:6072357
12. Virani S et al (2012) Cancer epigenetics: a brief review. ILAR J 53(3–4):359–369
13. Sen P et al (2016) Epigenetic mechanisms of longevity and aging. Cell 166(4):822–839
14. Benayoun BA, Pollina EA, Brunet A (2015) Epigenetic regulation of ageing: linking
environmental inputs to genomic stability. Nat Rev Mol Cell Biol 16(10):593–610
15. Ling C, Groop L (2009) Epigenetics: a molecular link between environmental factors and
type 2 diabetes. Diabetes 58(12):2718–2725
16. Landgrave-Gomez J, Mercado-Gomez O, Guevara-Guzman R (2015) Epigenetic mechanisms in neurological and neurodegenerative diseases. Front Cell Neurosci 9:58
17. Coppede F (2014) The potential of epigenetic therapies in neurodegenerative diseases. Front
Genet 5:220
18. Lee J et al (2013) Epigenetic mechanisms of neurodegeneration in Huntington’s disease.
Neurotherapeutics 10(4):664–676
19. Peedicayil J (2016) Epigenetic drugs for multiple sclerosis. Curr Neuropharmacol 14(1):3–9
20. Relle M, Foehr B, Schwarting A (2015) Epigenetic aspects of systemic lupus erythematosus.
Rheumatol Ther 2(1):33–46
21. Wu H et al (2015) The real culprit in systemic lupus erythematosus: abnormal epigenetic
regulation. Int J Mol Sci 16(5):11013–11033
22. Hedrich CM (2017) Epigenetics in SLE. Curr Rheumatol Rep 19(9):58
23. Klein K, Ospelt C, Gay S (2012) Epigenetic contributions in the development of rheumatoid
arthritis. Arthritis Res Ther 14(6):227
24. Bernstein BE, Meissner A, Lander ES (2007) The mammalian epigenome. Cell 128(4):
669–681
25. Wang Z et al (2008) Combinatorial patterns of histone acetylations and methylations in the
human genome. Nat Genet 40(7):897–903
26. Kaminskas E et al (2005) FDA drug approval summary: azacitidine (5-azacytidine, Vidaza)
for injectable suspension. Oncologist 10(3):176–182
27. Von Hoff DD, Slavik M, Muggia FM (1976) 5-Azacytidine. A new anticancer drug with
effectiveness in acute myelogenous leukemia. Ann Intern Med 85(2):237–245
28. Joeckel TE, Lubbert M (2012) Clinical results with the DNA hypomethylating agent
5-aza-2’-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Semin Hematol 49(4):330–341
29. Mann BS et al (2007) FDA approval summary: vorinostat for treatment of advanced primary
cutaneous T-cell lymphoma. Oncologist 12(10):1247–1252
30. Galanis E et al (2009) Phase II trial of vorinostat in recurrent glioblastoma multiforme: a
north central cancer treatment group study. J Clin Oncol 27(12):2052–2058
Integrated Chemoinformatics Approaches …
265